An Interactive Session on Emerging Data and Expert Insights on Hepatitis B

Statement of Need

Chronic hepatitis B (HBV) imposes a significant disease burden and identifying those at-risk for HBV is imperative to implementing effective care. More than half of people living with HBV are of Asian, Pacific Islander, or African descent, and HBV and the resulting hepatocellular cancer (HCC) contribute to substantial health disparities for these groups. While HBV is not curable, early detection, treatment, and monitoring can reduce the risk of liver disease and HCC.

Test your knowledge during this interactive CME Outfitters Live and OnDemand webcast featuring augmented reality animations that will reinforce the fibrotic consequence of untreated HBV. Data presentation and translation will showcase the importance of implementing routine screening protocols, optimizing efficacy and safety profiles of current agents when initiating or switching treatment, and routinely monitoring patients with HBV for disease progression HCC, and HBV reactivation.

Learning Objectives

At the end of this CME/CE activity, participants should be able to:

Implement routine screening protocols for HBV in the primary care setting to derive guideline-directed care.
Optimize efficacy and safety profiles of current agents when initiating or switching treatment in patients with HBV.
Routinely monitor patients with HBV every 6 months for disease progression, HCC, and HBV reactivation in patients who are immunosuppressed.

The following learning objectives pertain only to those requesting CNE or CPE credit:

Explain routine screening protocols for HBV in the primary care setting to derive guideline-directed care.
Summarize efficacy and safety profiles of current agents for the treatment of HBV.
Describe how to routinely monitor patients with HBV every 6 months for disease progression, HCC, and HBV reactivation in patients who are immunosuppressed.

Financial Support

Supported by an educational grant from Gilead Sciences, Inc.

Target Audience

Primary care physicians, nurse practitioners, PAs, nurses, and pharmacists

Credit Information

Physicians (ACCME) 1.0

CME Outfitters, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Note to Nurse Practitioners

Nurse Practitioners can apply for AMA PRA Category 1 Credit ™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit ™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Pharmacists/Pharmacy Tech (ACPE) 1.0

This application-based activity is approved for 1.0 contact hour (0.10 CEUs) of continuing pharmacy credit.

ABIM MOC 1.0

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 medical knowledge MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Kowdley reports that he receives research support from Janssen Pharmaceuticals, Inc. He is on the speakers bureau for Gilead Sciences, Inc. He is a consultant for Altimmune.

Dr. Lim reports he received research support from Allergan; Celgene Corporation; Eiger BioPharmaceuticals; GENFIT; Gilead Sciences, Inc.; and Intercept Pharmaceuticals, Inc.

Dr. Wang has no disclosures to report

Jeffrey Helfand, DO (peer reviewer) has no disclosures to report.

Mae Ochoa, RPh (peer reviewer) has no disclosures to report.

Noreen Iftikhar, MD (planning committee) has no disclosures to report.

Susan Perry (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Additional Formats

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

NOTE: Pharmacist CE Universal Activity Number, Enduring: 0376-0000-21-032-H01-P.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).